Rigel Pharmaceuticals [RIGL] stock is trading at $16.18, down -1.46%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The RIGL shares have gain 18.45% over the last week, with a monthly amount glided 19.41%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Previously, Citigroup downgraded its rating to Neutral on June 09, 2022. On June 08, 2022, downgrade downgraded it’s rating to Neutral and revised its price target to $1 on the stock. Cantor Fitzgerald downgraded its rating to a Neutral and decreased its price target to $1 on June 08, 2022. B. Riley Securities initiated its recommendation with a Neutral and recommended $4 as its price target on March 23, 2022. JP Morgan downgraded its rating to Neutral for this stock on November 09, 2020.
Rigel Pharmaceuticals [RIGL] stock has fluctuated between $7.12 and $17.30 over the past year. Currently, Wall Street analysts expect the stock to reach $1.5 within the next 12 months. Rigel Pharmaceuticals [NASDAQ: RIGL] shares were valued at $16.18 at the most recent close of the market. An investor can expect a potential drop of -90.73% based on the average RIGL price forecast.
Analyzing the RIGL fundamentals
Rigel Pharmaceuticals [NASDAQ:RIGL] reported sales of 130.30M for the trailing twelve months, which represents a growth of 37.03%. Gross Profit Margin for this corporation currently stands at 0.92% with Operating Profit Margin at -0.07%, Pretax Profit Margin comes in at -0.11%, and Net Profit Margin reading is -0.11%. To continue investigating profitability, this company’s Return on Assets is posted at -0.11, Equity is 0.47 and Total Capital is -0.13. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of-2.02.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 15.54 points at the first support level, and at 14.89 for the second support level. However, for the 1st resistance point, the stock is sitting at 16.80, and for the 2nd resistance point, it is at 17.41.
Ratios To Look Out For
For context, Rigel Pharmaceuticals’s Current Ratio is 1.62. Also, the Quick Ratio is 1.44, while the Cash Ratio stands at 0.61. Considering the valuation of this stock, the price to sales ratio is 2.18.
Transactions by insiders
Recent insider trading involved Santos David A, EVP, Chief Commercial Officer, that happened on Feb 05 ’24 when 8918.0 shares were sold. EVP, Chief Commercial Officer, Santos David A completed a deal on Feb 02 ’24 to sell 5601.0 shares. Meanwhile, EVP & Chief Financial Officer Schorno Dean L sold 7027.0 shares on Feb 05 ’24.
